Two monoclonal antibodies (MAb 53, MAb D7) were produced, each having specificity for Factor Vill-related antigen (FVIIIR:Ag), but exhibiting no inhibitory effect on either procoagulant activity or the ability of von Willebrand factor to agglutinate platelets in the presence of the antibiotic ristocetin. For quantification of FVIIIR:Ag, we used the antibodies in a competitive enzyme-linked immunosorbent assay (ELIsA L (1, 3) .8 Measurement of FVIIIR:Ag is important in the diagnosis of vWD and hemophilia A and has recently been used in the study of other disorders, including acute respiratory failure (4) and thrombotic thrombocytopenic purpura (5). In addition, current methods for detecting carriers of hemophilia A require accurate measurement of Factor VIII coagulant activity and FVIIIR Ag (6, 7). The techniques most frequently used for quanti1'ing FVIIJR:Ag are Laurell electroimmunoassay (EIA) (8) and immunoradiometric assay (IIusA) (9), both of which have disadvantages.
plasma Factor VIII, also called antihemophilic factor, is a complex of at least two proteins that are crucial to hemostasis. The most common hereditary bleeding disorders, hemophilia A and von Willebrand's disease (vWD), result from a deficiency of one or both components (1, 2). Hemophilia A, an X-linked clotting disorder, is characterized by deficiency or abnormality of the FVffl procoagulant protein and normal expression of von Willebrand factor (vWF) activities and of FVffl-antigen (FVfflR:Ag), the antigenic determi- have essentially no antigen, usually <10 units/L (1, 3). 8 Measurement of FVIIIR:Ag is important in the diagnosis of vWD and hemophilia A and has recently been used in the study of other disorders, including acute respiratory failure (4) and thrombotic thrombocytopenic purpura (5). In addition, current methods for detecting carriers of hemophilia A require accurate measurement of Factor VIII coagulant activity and FVIIIR Ag (6, 7) . The techniques most frequently used for quanti1'ing FVIIJR:Ag are Laurell electroimmunoassay (EIA) (8) and immunoradiometric assay (IIusA) (9) , both of which have disadvantages.
EIA is relatively insensitive and labor intensive. uut is very accurate and sensitive (2 units/L) (9), but the preparation of specific radiolabeled antibodies requires specialized equipment, specially trained personnel, and the handling and disposal of biohazardous materials. In addition, the labeled reagents have very limited shelf lives. More recently, several rapid and convenient assays for FVIIIR:Ag have been described, including a fluoroimmunoassay (10), an immunonephelometric technique (11) , and enzyme-linked immunosorbent assays (EusA) (12) (13) (14) (15) (16) (17) . ELISAS have been developed for a wide variety of antigens, and are technically simple, economical, and reproducible (18).
In most previously described ELISA5 for FVHIR:Ag, heterologous (rabbit) polyclonal antisera were used in either direct two-site (12, 13, 17) or indirect competitive (14, 15) immunometric assays. Ogata et al. (19) recently reported the use of a murine monoclonal antibody specific for Factor VIIIR:RC in a two-site ELISA for FVIIIR:Ag. The technique we evaluated here is an indirect competitive ELISA, in which binding of either of the two monoclonal anti-FVIIIR:Ag antibodies to solid-phase antigen is inhibited by free antigen in the test samples. The assay combines the previously mentioned attributes of an ELISA with the inherent advantages of monoclonal antibodies: high affinity, homogeneity, and minimal lot-to-lot variation. All assay components are commercially available.
Materials and Methods

Materials and Ancillary Procedures
Monoclorial
antibodies. Exclusive license for the D7 hybridoma cell line has been granted to Cooper Biomedical, Inc., who market the product as purified antibody to FVIIIR:Ag through Cappel Laboratories Division, West Chester, PA 19380. Although the commercial preparations we tested appeared to be comparable in all respects (titer, specificity, isotype, binding properties) to our own, we used murine ascitic fluid produced in our laboratory in all the studies with patients described herein. Optimal conditions and dilutions for the commercial product should be determined by the researcher.
Plasmas
and standards. Procoagulant activity and vWF assays. FVIII procoagulant activity was measured in an activated partial thromboplastin-time assay, with severe hemophilia A plasma as substrate (24). The ristocetin cofactor activity of vWF was assayed by the method of Reisner et al. (25) . To investigate the ability of the MAbs to inhibit biological activities, we mixed equal volumes of various dilutions of ascitic fluid and normal pooled plasma and incubated these mixtures for 2 h at 37 #{176}C. Test mixtures and controls were then assayed for residual activities as described above.
nm assays. The polyclonal rabbit antibody to FVIUR:Ag was prepared as previously described (26). In Ouchterlony double-diffusion, the antibody gave a single precipitin line against plasma from normal persons and hemophiliacs, and none against plasma from patients with severe vWD. Patients' samples were assayed for FVHIR:Ag by m#{174} as described by Hoyer and Trabold (9) , except that routinely the incubation was overnight at room temperature. The stabilized lyophilized pooled reference plasma we used as a standard in some assays was from Dr. C. R. Rizza (The Oxford Haemophilia Centre, Churchill Hospital, Oxford,
U.K.).
ELISA Protocol
Coating plates. The contents of one bottle of Koate#{174} 250 (Cutter Labs.), a lyophilized FVffl concentrate containing Assay procedure.
Dilutions of reference and test plasma in diluent/blocking solution were prepared in Titertek#{174} 96-well U-bottom microtiter plates (Flow Laboratories, McLean, VA 22102) with the use of an eight-channel pipetting device (Titertek#{174} multichannel pipette; Flow Laboratories). Reference (normal) plasmas were routinely assayed at seven dilutions (20-, 30-, 40-, 60-, 80-, 160-, and 320-fold). Most test samples were assayed at four serial dilutions (20-, 40-, 80-, and 160-fold). Because F'VIIIR:Ag concentrations in Hz vWD patients from different kindreds vary from very low to near normal, these plasmas were assayed at six doubling dilutions (five-to 160-fold). The plasmas from patients with severe vWD were assayed at five doubling dilutions (five-to 160-fold). After dilution, each well contained 100 L of sample. An additional well, containing 100 L of diluentiblocking solution only, was set up with each sample to serve as a positive control and to indicate maximum color development. Murine ascitic fluid that contained monoclonal antibody to FVIIIR:Ag was diluted in diluent/blocking solution (400 000-fold for MAb D7, 5000-fold for MAb 53), and 100 L was dispensed into each of the wells containing sample dilutions and controls. The plates were covered, and the mixtures were preincubated for 1 hat 37 #{176}C. Working dilutions of the antibodies were stable for at least two weeks at 4 #{176}C.
Immediately before the end of the preincubation period, the blocking solution was shaken out of the antigen-coated assay plates. The plates were washed two or three times with the wash solution described previously, and tapped to remove liquid (plates should be used within 5 mm after this step). All samples were assayed in duplicate. We added 50 L from each of the incubation mixtures to two coated wells. On each assay plate we included two negative control wells, containing normal plasma (routinely diluted 10-fold in controls) plus buffer or normal plasma plus diluted nommmune murine ascitic fluid (Cappel Laboratories), or both. The plates were covered and left overnight at room temperature. After three washes, we added 50 pL per well of a 100-fold dilution of peroxidase-conjugated affinity-purified goat anti-mouse IgG (Hybri-Clonal"' Kit reagent; Kirkegaard & Perry) to each plate at timed intervals. After incubation for exactly 1 h at room temperature, each plate was washed seven times. 
Results
Analytical Variables
Characterization of monoclonal antibodies.
MAbs D7 and 53 were both positive by ELISA when FVIII concentrate or purified FVfflR:Ag was used as solid-phase antigen, but negative with fibrinogen, fibronectin, and albumin. In the radioimmunometric "sandwich" assay, reactivity was seen with FVffl concentrate, purified FVIIIR:Ag, and with normal, Hz vWD, and hemophilic plasmas as the source of antigen, but not with plasmas from severe vWD or with fibrinogen, fibronectin, albumin, or human Cohn Fraction II (immunoglobulin). When ascitic fluids containing either MAb were run against subclass-specificantisera in Ouchterlony double-diffusion, precipitin lines were seen only with the anti-IgG1. To determine the isotype of the antibodies specific for FVIIIR:Ag, we substituted subclass-specificantisera in the coating step in the "sandwich" assay. Binding of radiolabeled antibody was detected only with the anti-IgG1 coat.
We found that neither antibody inhibited either FVIH activity in coagulation assays, or vWF activity as measured in a ristocetin cofactor assay. Indirect immunofluorescence showed that both antibodies bound to endothelial cells in the pattern characteristic of FVIHR:Ag, but did not bind to other cell types (27) .
Assay characteristics. Polyvinyl chloride and Immulon II polystyrene plates bound FVHIR:Ag with equal affinity and stability. We chose Immulon II for the studies with patients because the more uniform optical properties gave somewhat less intra-assay variation. Interassay variation was evaluated both by repeated assay of a commercial reference standard (Thrombo-Screen), and by analysis of dilution points on the normal pooled plasma reference curves; intra-assay variation was studied only by the latter method. All CVs for the ELISA assays with either antibody were <11% (Table 1) .
Comparison
of monoclonal antibodies. Additional assays with Thrombo-ScreenUniversalCoagulation Reference Plasma gave the following results for interassay variation: D7 (n = 9): 997 ± 94 units of FVIIIR:Agper liter (mean ± SD). CV = 9.47%:53 (n = 10): 1042 ± 82 units/I, CV = 7.85%. representing a mean value for all samples at that dilution. The 53-and D7-zusA dose-response curves for normal plasma are parallel (p = 0.738), as are the normal and Hz vWD curves for each antibody (p = 0.299 for 53; p = 0.061 for D7). Linearity of dose response was consistently seen with both antibodies when we assayed plasmas from severe vWD diluted 10-fold or less, but the dose-response curves did not parallel those for reference standards or for normal and Hz vWD plasmas (Figure 2 We concurrently assayed 78 samples (from 63 normal subjects or potential hemophilia A carriers, four with hemophilia A, and 11 with vWD) by D7-ELISA and mrs, using our normal pooled plasma as the reference standard. An additional 50 samples (all from normal subjects or potential hemophilia A carriers), assayed previously with use of the standard from the Oxford Haemophilia
Centre as part ofan extensive hemophilia A-carrier detection study, were also assayed by D7-EusA. After determining that the Oxford standard and normal pooled-plasma dose-response curves were parallel, we applieda correction factor to these50 IRIr&A values to account for the quantitative difference between standards.
Scatter diagrams of D7-EusA values vs m values were then generated for the 67-sample group calculated from the normal pooled-plasma standard and for the 50-sample group with corrected concentrations from the Oxford standard. Because analysis of the regression lines generated by these two groups of data revealedboth the 
Assay Use in Other Systems
Both ELISA assays were alsoused,with equivalent sensitivity, in quantifying FVIIIR:Ag in canine, porcine, and bovine plasma. The dose-response curves paralleled those for human plasma. The data suggest that the epitope is highly conserved evolutionarily.
Discussion
Using specific heterologous antisera, several groups of investigators have studied the utility of ELISA inthequanti- hemophilia A patients, the mean values being generally higher when the monoclonal antibody was used. For vWD patients, however, the correlation coefficient was 0.55 (p < 0.05), with the rabbit antiserum detecting significantly more antigen in four patients' plasmas. These authors suggested that a structural difference in the FVHIR:Ag molecule in these patients might account for this discrepancy.
Our method is similar in concept to ELISA5 previously described (14, 15) . However, the use of protein-binding Immulon II makes it possible to coat assay plates rapidly and efficiently at physiological pH, and the use of microtiter plates both for sample dilution and assay results in economy of reagents and sample. The use of monoclonal antibodies has also simplified the technique. It is not necessary to use purified or partly purified FVIIIR:Ag to coat the assay plates, owing to the single specificity of monoclonal antibodies. The observations that these MAbs (a) do not appear to inhibit biological activities and (b) recognize an antigenic determinant conserved in several mammalian species suggest that the epitope(s) may be located outside the active site(s) of FVHI and may be important in maintaining the structural integrity of the vWF molecule. 
